MDT

85.94

-1.78%↓

118.37

-1.82%↓

VEEV

167.17

-0.34%↓

HQY

84.38

+1.13%↑

NEOG

9.26

-2.83%↓

MDT

85.94

-1.78%↓

118.37

-1.82%↓

VEEV

167.17

-0.34%↓

HQY

84.38

+1.13%↑

NEOG

9.26

-2.83%↓

MDT

85.94

-1.78%↓

118.37

-1.82%↓

VEEV

167.17

-0.34%↓

HQY

84.38

+1.13%↑

NEOG

9.26

-2.83%↓

MDT

85.94

-1.78%↓

118.37

-1.82%↓

VEEV

167.17

-0.34%↓

HQY

84.38

+1.13%↑

NEOG

9.26

-2.83%↓

MDT

85.94

-1.78%↓

118.37

-1.82%↓

VEEV

167.17

-0.34%↓

HQY

84.38

+1.13%↑

NEOG

9.26

-2.83%↓

Home・Akcijų sąrašas・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

21.46

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

21.46

Max

21.47

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-1.6M -21M
Pardavimai	14M 54M
Pelno marža	-39.611
Darbuotojai	178
EBITDA	-3.8M -23M

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	-2.84% downside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	1B 2.2B
Ankstesnė atidarymo kaina	21.46
Ankstesnė uždarymo kaina	21.46

Naujienos nuotaikos

By Acuity

50%

167 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

6.26 / 7.47 Palaikymas ir pasipriešinimas

Day One Biopharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-15 23:14; UTC

Uždarbis

Battery Maker CATL First-Quarter Net Rose on Strong Demand

2026-04-15 23:14; UTC

Uždarbis

Battery Maker CATL First Quarter Net Rose On Strong Demand

2026-04-15 17:13; UTC

Pagrindinės rinkos jėgos

Tesla Shares Rise on Completion of AI5 Chip Design Process

2026-04-15 23:39; UTC

Rinkos pokalbiai

Nikkei May Rise After Gains on Wall Street -- Market Talk

2026-04-15 23:35; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Rises Amid Hopes for More U.S.-Iran Talks -- Market Talk

2026-04-15 22:41; UTC

Uždarbis

CATL 1Q Net CNY20.74 Vs. Net CNY13.96B >300750.SZ

2026-04-15 22:38; UTC

Uždarbis

CATL 1Q Rev CNY129.13B Vs. CNY84.70B >300750.SZ

2026-04-15 22:15; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-15 22:15; UTC

Rinkos pokalbiai

J.B. Hunt Flag Fundamental Shift in 1Q -- Market Talk

2026-04-15 22:14; UTC

Uždarbis

Lens Technology Results Weighed by Lower Rev From Smartphone, Computer Business >300433.SZ

2026-04-15 22:12; UTC

Uždarbis

Lens Technology 1Q Oper Income CNY14.14B Vs. CNY17.06B>300433.SZ

2026-04-15 22:11; UTC

Uždarbis

Lens Technology 1Q Loss CNY149.60M Vs. Net CNY428.88M >300433.SZ

2026-04-15 22:11; UTC

Uždarbis

Lens Technology Swings to Loss in 1Q>300433.SZ

2026-04-15 22:07; UTC

Uždarbis

Big Bank Earnings Show Consumers Are on Solid Ground -- Against All Odds -- Barrons.com

2026-04-15 21:34; UTC

Įsigijimai, susijungimai, perėmimai

Skild AI Acquires Zebra Technologies' Robotics Automation Business

2026-04-15 21:29; UTC

Karštos akcijos

Stocks to Watch: Bank of America, Live Nation, Snap, Hermès -- WSJ

2026-04-15 20:50; UTC

Rinkos pokalbiai

Uždarbis

Financial Services Roundup: Market Talk

2026-04-15 20:30; UTC

Uždarbis

PepsiCo Cuts Prices, Revamps Products. Earnings Will Show if It's Working. -- Barrons.com

2026-04-15 20:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-04-15 20:06; UTC

Rinkos pokalbiai

Silver Inches Up as Attention Turns to World Deficit -- Market Talk

2026-04-15 19:46; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Jamie Dimon Says JPMorgan Stock Isn't Cheap. Why the Bank Is Still Buying Back Billions. -- Barrons.com

2026-04-15 19:25; UTC

Rinkos pokalbiai

Automakers' 1Q Earnings Could Give Clues to EV Comeback -- Market Talk

2026-04-15 19:00; UTC

Rinkos pokalbiai

U.S. Natural Gas Edges Up Ahead of Storage Data -- Market Talk

2026-04-15 18:58; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Settles Flat As Market Awaits Conflict Developments -- Market Talk

2026-04-15 18:11; UTC

Įsigijimai, susijungimai, perėmimai

Three Lessons From Amazon's Blockbuster Deal to Buy Globalstar -- Barrons.com

2026-04-15 17:45; UTC

Įsigijimai, susijungimai, perėmimai

Apple CEO Tim Cook Buys Nike Stock. His Last Purchase Didn't Go So Well. -- Barrons.com

2026-04-15 16:58; UTC

Uždarbis

Bank of America's Wealth Management Profits Rise Amid 'Resilient' U.S. Economy -- Barrons.com

2026-04-15 16:52; UTC

Uždarbis

Snap and Other Companies Blame AI for Layoffs. Is It Just a Convenient Excuse? -- Barrons.com

2026-04-15 16:46; UTC

Rinkos pokalbiai

Svarbiausios naujienos

U.S. Crude Oil Stocks Finally See Drawdowns -- Market Talk

2026-04-15 16:37; UTC

Rinkos pokalbiai

Uždarbis

Global Equities Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Day One Biopharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

-2.84% į apačią

12 mėnesių prognozė

Vidutinis 20.86 USD -2.84%

Aukščiausias 21.5 USD

Žemiausias 17 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Day One Biopharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

9 ratings

Pirkti

Laikyti

Parduoti

Remiantis 9 analitikų, pateikusių Day One Biopharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

6.26 / 7.47Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Rinkos nuotaikos

By Acuity

167 / 348 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.